ZYBERNO
Stock Report
Updated Sep 1, 2026

CLIMB BIO, INC. (CLYM)

Healthcare • NASDAQ

$14.57

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
32.0/100
WEAK BUSINESS
CLIMB BIO, INC. (CLYM) scores 32/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-31.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-24.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CLIMB BIO, INC. (CLYM) stock report — Zyberno Score 32/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:14.57
Market Cap:$1.11B

Valuation Multiples (2)

P/B Ratio:4.63x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.07B

Price Action & Momentum (3)

Momentum Percentile:100 / 100
% of 52-Week High:79.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-30.8%
Reinvestment Rate:-18.9%
Fundamental Growth Rate (g):4.7%

Margin Analysis (1)

Ebitda Margin:-795.1%

Yield Metrics (2)

Earnings Yield:-$5.63
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-237.0%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:31.45x
Quick Ratio:31.45x
Cash Ratio:7.43x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:180,702,000.00
Cash And Cash Equivalents:44,107,000.00
Long Term Debt:$813.00K
Net Debt:-$42.79M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$8.13M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$64.76M

Bottom Line Performance (3)

-$57.62M
Income Before Tax:$0.00
Ebitda Ttm:-64,661,000.00

Operating Expenses (5)

Operating Expenses:64,758,000.00
R And D Expense:41,898,000.00
Sga Expense:22,860,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:515.2%
Sga To Revenue Percentage:281.1%
Ebitda Margin:-795.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$246.29M
Current Assets:$186.64M
Ppe Net:695,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:6,747,000.00
Current Liabilities:5,934,000.00
Long Term Debt:$813.00K
Short Term Debt:$501.00K

Equity & Capital (3)

Equity:$239.55M
Retained Earnings:-$316.95M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,133,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,481,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$53.30M-$54.54M

Investment Activities (1)

Investing Cash Flow:-$12.96M

Financing Activities (3)

Financing Cash Flow:$5.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.82
-$0.82
Earnings Per Share Ttm:-$0.76

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.11
Operating Cash Flow Per Share:-$0.20

Book Value & Capital (2)

Book Value Per Share:$3.15
Cash Per Share:0.58

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.04x
Working Capital Turnover Ttm:0.05x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:50.85
Cash Conversion Cycle:-2,048.85
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-18.9%
Fundamental Growth Rate (g):4.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):11.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:CLYM
Company Name:CLIMB BIO, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:76.15M
Shares Outstanding Basic:76.15M
Shares Outstanding Diluted:76.15M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:10:20 UTC
Data Timestamp:2026-09-01T16:10:20.425324
Scroll to Top